Peptides are one of the hottest trends in "biohacking" right now.
The problem: most of those being injected today still lack robust clinical evidence. They are marketed for everything from fat burning and recovery to anti-aging and "regeneration". The majority of the peptides in the wellness world have never been tested in large clinical studies in humans.
Peptides that actually have strong evidence
It is important to distinguish between medical drugs and experimental wellness peptides.
Examples of peptides with clear clinical evidence:
- Insulin, the cornerstone of diabetes treatment for over 100 years
- GLP-1 analogues (e.g. semaglutide), which have revolutionised the treatment of diabetes and obesity
Here there are large randomised studies and regulatory approval. In other words: peptides can be powerful medicine, when they are scientifically tested.
Trendy peptides, but weak evidence
At the same time, several peptides have become popular in biohacking and longevity circles.
Examples:
- BPC-157, often called the "Wolverine peptide" for its claimed tissue regeneration; the evidence is based mainly on animal studies
- TB-500, marketed for healing and recovery but lacking larger clinical studies
- CJC-1295 / Ipamorelin, used to stimulate growth hormone; long-term safety is unclear
- MOTS-c and AOD-9604, popular in longevity circles but still experimental
Many are also sold in regulatory grey zones as "research chemicals".
The problem: the evidence gap
Drug development normally takes 10 to 15 years of clinical studies. But in the peptide world, social media and biohacking culture have sometimes reversed the order: first hype, then science. The result is a growing gap between medical evidence and wellness marketing.
In the unregulated market, the risks can include:
- incorrect dosing or contamination
- hormonal disturbances
- unknown drug interactions
- a lack of long-term safety data
Longevity medicine is developing rapidly, and peptides may play an important role in the future. But until more data is available, we need to distinguish between clinical medicine and biohacking experiments. Longevity should be about evidence, safety and long-term health, not about the next trend.
